ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
34.68
-1.17%
US Tech 100
16,913.60
-2.29%
S&P 500
5,035.69
-1.57%
US Dollar vs CAD
1.37783
0.81%
Bitcoin
60,339.02
-5.48%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. Merck and Co Inc (MRK)

  7. Merck and Co Inc (MRK) News

MRK

Merck (MRK)

Merck and Co Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:MRK
DateTimeSourceHeadlineSymbolCompany
04/29/20248:00AMBusiness WireMerck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for AdultsNYSE:MRKMerck and Co Inc
04/25/20243:40PMIH Market NewsU.S. Stocks Climb Well Off Worst Levels But Close Mostly LowerNYSE:MRKMerck and Co Inc
04/25/20248:09AMIH Market NewsFutures Pointing To Sharply Lower Open On Wall StreetNYSE:MRKMerck and Co Inc
04/25/20246:52AMIH Market NewsSouthwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on EarningsNYSE:MRKMerck and Co Inc
04/25/20245:30AMBusiness WireMerck Announces First-Quarter 2024 Financial ResultsNYSE:MRKMerck and Co Inc
04/19/20246:04AMPR Newswire (Canada)Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-contaNYSE:MRKMerck and Co Inc
04/19/20246:04AMPR Newswire (Canada)Santé Canada approuve KEYTRUDA® comme traitement de première intention, en association avec une chimiothérapie à base de fluoropyrimidine et de platine, des adultes atteints d'un adénocarcinome gastrique ou de la jonction gastro-œsophagienne (JGO) HNYSE:MRKMerck and Co Inc
04/10/20246:13AMIH Market NewsDelta Generates US$37 Million Profit in Q1, Google and Intel Unveil Cutting-Edge AI Chips, and More NewsNYSE:MRKMerck and Co Inc
04/04/20245:45AMBusiness WireMerck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung CancerNYSE:MRKMerck and Co Inc
04/03/20247:00AMBusiness WireREJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian CancerNYSE:MRKMerck and Co Inc
04/01/20245:45AMBusiness WireMerck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25NYSE:MRKMerck and Co Inc
03/28/20245:45AMBusiness WireEuropean Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in AdultsNYSE:MRKMerck and Co Inc
03/27/20245:54AMIH Market NewsGameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More NewsNYSE:MRKMerck and Co Inc
03/26/20245:21PMBusiness WireFDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)NYSE:MRKMerck and Co Inc
03/21/20245:45AMBusiness WireMerck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung CancerNYSE:MRKMerck and Co Inc
03/19/20248:00AMBusiness WireMerck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in AdultsNYSE:MRKMerck and Co Inc
03/15/20243:23PMPR Newswire (US)FarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring PlatformNYSE:MRKMerck and Co Inc
03/15/20245:45AMBusiness WireMerck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical CancerNYSE:MRKMerck and Co Inc
03/13/20242:00AMBusiness WireMerck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9NYSE:MRKMerck and Co Inc
03/11/20247:15AMBusiness WireMerck Completes Acquisition of Harpoon Therapeutics, Inc.NYSE:MRKMerck and Co Inc
03/06/20249:25AMBusiness WireGilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24NYSE:MRKMerck and Co Inc
03/05/20248:03AMIH Market NewsFutures Pointing To Continued Weakness On Wall StreetNYSE:MRKMerck and Co Inc
03/05/20245:45AMBusiness WireMerck to Participate in the Barclays 26th Annual Global Healthcare ConferenceNYSE:MRKMerck and Co Inc
03/04/20245:45AMBusiness WireMerck to Participate in the Leerink Partners Global Biopharma Conference 2024NYSE:MRKMerck and Co Inc
02/27/20245:45AMBusiness WireMerck to Participate in the TD Cowen 44th Annual Health Care ConferenceNYSE:MRKMerck and Co Inc
02/23/20245:20AMBusiness WireMerck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of RecurrenceNYSE:MRKMerck and Co Inc
02/20/20243:14PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:MRKMerck and Co Inc
02/20/20245:45AMBusiness WireFDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial CarcinomaNYSE:MRKMerck and Co Inc
02/15/20243:03PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:MRKMerck and Co Inc
02/15/20243:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:MRKMerck and Co Inc
 Showing the most relevant articles for your search:NYSE:MRK

Your Recent History

USOTC
CBDW
1606 (PK)
USOTC
VXIT
Virexit Technologies (PK)
USOTC
ELTP
Elite Pharmaceuticals (QB)
COIN
BTCUSD
Bitcoin
USOTC
EGOC
Energy One (PK)
USOTC
BLEG
Branded Legacy (PK)
USOTC
CBIA
Canopus Biopharma (PK)
USOTC
NSAV
Net Savings Link (PK)
USOTC
CNNA
Cann American (CE)
NASDAQ
AGBA
AGBA
USOTC
BLFR
BlueFire Equipment (PK)
NASDAQ
AMRN
Amarin
USOTC
TONR
Tonner One World (PK)
USOTC
SPZI
Spooz (PK)
USOTC
GDVM
Global Developments (PK)
NASDAQ
PLUG
Plug Power
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved